Clinical Observations on the Association Between Diagnosis of Lung Cancer and Serum Tumor Markers in Combination

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 7, 2013, Pages 4369-4371

  Wang, Wen Jing ^a   Tao, Zhen ^a   Gu, Wei ^b   Sun, Li Hua ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

CA199; CEA; CYFRA21 1; Lung cancer; NSE

Indexed keywords

ANTIGEN CYFRA21.1; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; ENOLASE; TUMOR ANTIGEN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; CASE CONTROL STUDY; CHILD; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84885441946     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.7.4369     Document Type: Article

References (15)

1. Ardizzoni A, Cafferate MA, Tiseo M, et al (2006). Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer, 107, 2842-9.
2. Bilgin E, Dizdar Y, Serilmez M, et al (2013). For which cancer types can neuron-specific enolase be clinically helpful in Turkish patients? Asian Pac J Cancer Prev, 14, 2541-4.
3. Buccheri G, Eerrigno D (2002). Lung tumor markers in oncology practice: a study of TPA and CA125. Br J Cancer, 87, 1112-8.
4. Cho JY, Sung HJ (2009). Proteomic approaches in lung cancer biomarker development. Expert Rev Proteomics, 6, 27-42.
5. Fletcher CD, Berman JJ, Corless C, et al (2002). Diagnosis of gastrointestinal stromal tumoes: a consensus approach. Hum Patnol, 33, 459-65.
6. Hu LA, Fu Y, Zhang DN, et al (2013). Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2563-6.
7. Kav S, Tokdemir G, Tasdemir R, et al (2012). Patients with cancer and their relatives beliefs, information needs and information-seeking behavior about cancer and treatment. Asian Pac J Cancer Prev, 13, 6027-32.
8. Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with Stage III non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5.
9. Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8.
10. Malik PS, Sharma MC, Mohanti BK, et al (2013). Clinico-pathological profile of lung cancer at AIIMS: a changing paradigm in India. Asian Pac J Cancer Prev, 14, 489-94.
11. Oguz A, Unal D, Tasdemir A, et al (2013). Lack of any association between blood groups and lung cancer, independent of histology. Asian Pac J Cancer Prev, 14, 453-6.
12. Pan JB, Hou YH, Zhang GJ (2013). Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients. Asian Pac J Cancer Prev, 14, 695-700.
13. Parkin DM, Brary FB, Pisani P (2005). Global cancer statistics. Cancer J Clin, 55, 74-108.
14. Ramshankar V, Krishnamurthy A (2013). Lung cancer detection by screening - presenting circulating miRNAs as a promising next generation biomarker breakthrough. Asian Pac J Cancer Prev, 14, 2167-72.
15. Schneider J, Bitterlich N, Velcovsky HG, et al (2002). Fuzzy logic based tumor marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol, 7, 145-51.